|View printer-friendly version|
|July 31, 2000 3:28 p.m.|
|Teva Pharmaceutical Industries, Ltd. and Aventis Pharmaceuticals Announce 2Q 2000 Record Sales of Copaxone®|
Partnership builds on success, plans aggressive growth
Jerusalem, Israel and Parsippany, N.J., July 31, 2000 - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) and Aventis Pharmaceuticals today announced record North America in-market sales of Copaxone® of $53 million in the 2nd quarter of 2000, up 60% from the comparable quarter of 1999. Total global in-market sales of Copaxone® were $59.4 million in the quarter.